secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001171843-25-003153
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus reports Q1 net loss $24.5M; imdusiran functionally cures 8 cHBV patients
--------------------------------------------------------------------------------

- Net loss $24.5M ($0.13/share) vs $17.9M ($0.10) in Q1 2024; revenue $1.8M vs $1.5M.
- Cash, equivalents & securities $112.7M as of Mar 31, down from $122.6M at Dec 31, 2024.
- Imdusiran combo therapy functionally cured 8 cHBV patients to date; 2 received no interferon.
- AB-101 oral PD-L1 inhibitor achieved 100% receptor occupancy in 11 of 13 healthy subjects at 40mg.
- Moderna U.S. jury trial set for Sep 29, 2025; claim construction for Pfizer/BioNTech expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325003153/0001171843-25-003153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325003153/f8k_051425.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-003153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer